12:00 AM
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Winfuran nalfurafine regulatory update

EMA accepted for review an MAA from Toray for Winfuran nalfurafine to treat uremic pruritus. The injectable formulation of the kappa opioid receptor agonist has Orphan Drug designation in the EU to...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >